Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Human Pathology|September 24, 2023
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinomaSvenja Kolb, Inga Hoffmann, Nanna Monjé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2013
Ki67 measured after neoadjuvant chemotherapy for primary breast cancerGunter von Minckwitz, Wolfgang D Schmitt, Sibylle Loibl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast CancerBruno V Sinn, Sibylle Loibl, Claus A Hanusch, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer TrialThomas Karn, Tobias Meissner, Karsten E Weber, et al.
The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
NPJ Breast Cancer|June 25, 2019
SET<sub>ER/PR</sub>: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancerBruno V Sinn, Chunxiao Fu, Rosanna Lau, et al.
Nature Medicine|February 9, 2016
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinomaElisa M Noll, Christian Eisen, Albrecht Stenzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2014
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersCarsten Denkert, Gunter von Minckwitz, Jan C Brase, et al.
European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trialsSonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.
Pageof 5